// App-Quantinova.ai

564 : Outcomes of Non-Myeloablative HLA-Haploidentical Bone Marrow Transplant with Thiotepa and Post-Transplant Cyclophosphamide in Children and Adults with Severe Sickle Cell Disease, a Phase II Trial: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC2)

Researchers

Presenter

  • Adetola A. Kassim

Principal Investigators

  • Ali Debsan Alahmari

  • Michael J. Eckrich

  • Rabi Hanna

  • Nathalie Dhedin

  • Biljana N. Horn

  • Vandy Black

  • Roseane V Gouveia

  • Adriana Seber

  • Belinda Pinto Simes

  • Thalita Cristina de Mello Costa

  • Renato Guerino-Cunha

  • Carmem M. S. Bonfim

  • Roberto Luiz da Silva

  • Nelson Hamerschlak

  • Juliana Folloni Fernandes

  • Michael Kent

  • Satya Prakash Yadav

  • Erfan Nur

  • Mohsen Alzahrani

  • Ben Carpenter

  • William Tse

  • Maria Isabel

  • Hemalatha G Rangarajan

  • Ibrahim Ahmed

  • Adeseye Michael Akinsete

  • Courtney D. Fitzhugh

  • Kathryn A. Culos

  • Leena Karnik

  • James Connelly

  • Carrie Kitko

  • Jennifer Andrews

  • Karina L Wilkerson

  • Robert Brodsky

  • Tatsuki Koyama

  • Michael R. DeBaun

Medical Centers

  • Vanderbilt-Meharry Center of Excellence in Sickle Cell Disease, Nashville, TN

  • Division of Epidemiology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN

  • Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN

  • Department of Paediatrics, St. Mary's Hospital,Imperial College Healthcare Trust,London,United Kingdom

  • King Faisal Hospital & Research Ctr., Riyadh, SAU

  • Pediatric Blood and Marrow Transplantation Program, Texas Transplant Institute at Medical City Dallas, San Antonio, TX

  • Blood and Marrow Transplant Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

  • St-Louis Hospital, APHP, Adolescents and Young Adults Hematology Department, Paris, France

  • UF Shand's Children Hospital, University of Florida, Gainesville, FL

  • University of Florida College of Medicine, Newberry, FL

  • Department of Pediatrics, Division of Pediatric Hematology and Oncology, University of Florida College of Medicine, Gainesville, FL

  • Hospital Sao Camilo Pompeia, Pediatric Oncology and Hematopoietic Cell Transplantation, São Paulo, Brazil

  • Hospital Samaritano, Sao Paulo, SP, Brazil

  • Department of Medicine, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil., Ribeirão Preto, Brazil

  • Center for Cell-Based Therapy, Hemotherapy Center of Ribeirão Preto, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil., Ribeirão Preto, Brazil

  • School of Medicine of Ribeirão Preto, University of São Paulo, São José Do Rio Preto, Brazil

  • Ribeirão Preto Medical School, University of São Paulo, Departments of Medical Imaging and Hematology /Clinical Oncology, São Paulo, Brazil

  • Federal University of Parana, Curitiba, Brazil

  • Hospital Nossa Senhora das Gracas, Curitiba, Brazil

  • IBCC Oncologia (Instituto Brasileiro de Controle do Câncer), São Paulo, Brazil

  • Hospital Israelita Albert Einstein, Sao Paulo, Brazil

  • Hospital Israelita Albert Einstein, Sao Paulo, Brazil

  • Department of Hematology and Bone Marrow Transplantation, Hospital Israelita Albert Einstein, Hematology unit, São Paulo, Brazil

  • Atrium Health Levine Children's Hospital,Charlotte,Stati Uniti

  • Pediatric Hemato-Oncology & BMT, Medanta The Medicity, Gurgaon, India

  • Pediatric Hemato-Oncology & BMT, Fortis Memorial Research Institute, Gurgaon, India

  • Department of Clinical Hematology, Slotervaart Hospital, Amsterdam, Netherlands

  • Department of Hematology,Amsterdam University Medical Center, location VU Medical Center,Amsterdam,Netherlands

  • Saudi Society of Blood & Marrow Transplantation (SSBMT), Riyadh, Saudi Arabia

  • Division of Adult Hematology and SCT, Department of Oncology, King Abdulaziz Medical City, Riyadh, Saudi Arabia

  • University College London Hospitals NHS Trust, London, United Kingdom

  • Bone Marrow Transplant, University of Louisville, Louisville, KY

  • The University of Louisville, Louisville, KY

  • Vall d' Hebron Hospital, Department of Hematology / Oncology, Barcelona, Spain

  • Hematology/Oncology/BMT, Nationwide Children's Hospital, Columbus, OH

  • Division of Pediatric Hematology, Oncology, Blood and Marrow Transplant, Nationwide Childrens Hospital, Columbus, OH

  • Nationwide Children's Hospital, Columbus, OH

  • Division of Pediatric Hematology, Oncology, Blood and Marrow Transplant, Children's Mercy Hospital, Kansas City, MO

  • College of Medicine, Division of Pediatric Hematology & Oncology, Lagos University Teaching Hospital, Lagos, Nigeria

  • Cellular and Molecular Therapeutics Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD

  • Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN

  • Paediatrics, St Mary's Hospital, London, United Kingdom

  • Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN

  • Pediatric Hematology/Oncology Division, Vanderbilt-Ingram Cancer Center, Nashville, TN

  • Vanderbilt University Medical Center, Nashville, TN

  • Vanderbilt University Medical Center, Nashville, TN

  • Hematology/Oncology Department Sickle Cell Disease Center of Excellence, Vanderbilt University Medical Center, Nashville, TN

  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD

  • Division of Gastroenterology, Johns Hopkins University School of Medicine, Baltimore, MD

  • Department of Biochemistry, Vanderbilt University, Nashville, TN

  • Vanderbilt-Meharry-Matthew Walker Center of Excellence in Sickle Cell Disease, Vanderbilt University School of Medicine, Nashville, TN

Locations

  • United States

  • United Kingdom

  • France

  • Brazil

  • India

  • Netherlands

  • Saudi Arabia

  • Spain

  • Nigeria

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Sickle cell anemia

  • Stroke

  • Graft-versus-host disease

Biomarkers

  • Stearoyl-CoA desaturase

Drug/Treatment

  • Mycophenolate mofetil

  • CKD-4101

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Mycophenolic acid

  • fludarabine tablet

  • Filgrastim

  • Rapacan

  • Thiotepa

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT01850108

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved